NASDAQ · Biotechnology

Zymeworks Inc. (ZYME) Stock

$25.26 -4.79% NASDAQ: ZYME Healthcare

Valuation

MetricValue
Price$25.26
Market Cap$1.86B
P/E Ratio-13.59
P/B Ratio24.93
P/S Ratio54.39
EPS (TTM)$-1.37
52-Week High$31.34
52-Week Low$16.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-72.07%
ROA-37.78%
ROCE-44.48%
Gross Margin-67.01%
Operating Margin-19.57%
Net Margin-404.00%
Debt/Equity3.34
Current Ratio10.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$27.0M$412.0M$76.0M$76.0M$106.0M
Operating Profit$-216.0M$131.0M$-138.0M$-137.0M$-93.0M
Net Profit$-212.0M$124.0M$-119.0M$-123.0M$-81.0M
EPS$-4.61$1.90$-1.72$-1.62$-1.08
Op Margin-808.2%31.6%-181.6%-179.7%-87.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$389.0M$649.0M$581.0M$463.0M$347.0M
Total Liabilities$140.0M$156.0M$116.0M$124.0M$78.0M
Cash$202.0M$401.0M$158.0M$66.0M$41.0M
Borrowings$32.0M$28.0M$27.0M$19.0M$18.0M

Latest News

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 GlobeNewswire · Jul 16, 2026 Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why Insider Monkey · Jul 15, 2026 Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run Simply Wall St. · Jul 1, 2026 Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? Insider Monkey · Jun 30, 2026 Theravance Stock Down 3% After Zymeworks Announces Buyout Zacks · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-192.0M$144.0M$-118.0M$-110.0M$-33.0M
Investing Cash Flow$131.0M$-67.0M$-211.0M$36.0M$25.0M
Financing Cash Flow$8.0M$1.0M$6.0M$-20.0M$-42.0M
Net Cash Flow$-40.0M$199.0M$-243.0M$-91.0M$-25.0M
Free Cash Flow$-206.0M$131.0M$-122.0M$-113.0M$-35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.20
EV / EBITDA-15.07
FCF Yield-5.94%
Quick Ratio6.32
Interest Coverage-75.30
Return 1Y63.12%
Return 3Y215.43%
Return 5Y-34.23%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics SA $1.59 +11.97% -2.14 $202.23M 0.00%
ALXOALX Oncology Holdings Inc. $1.18 +4.42% -1.08 $158.78M 0.00%
CBIOCrescent Biopharma, Inc. $14.12 +4.67% -1.84 $524.47M 0.00%
CGENCompugen Ltd. $2.12 -1.40% 6.15 $200.45M 0.00%
CLDXCelldex Therapeutics, Inc. $29.30 -3.71% -7.26 $1.95B 0.00%

About Zymeworks Inc.

Zymeworks Inc. (ZYME) stock trades at $25.26 with a market capitalization of $1.86B. The stock is valued at a price-to-earnings (P/E) ratio of -13.59, price-to-book of 24.93, price-to-sales of 54.39. Over the past 52 weeks the stock has ranged between $16.00 and $31.34, and currently trades 19.4% below its 52-week high.

On profitability, Zymeworks Inc. generates a return on equity (ROE) of -72.07%, return on capital employed of -44.48%, an operating margin of -19.57%, a net profit margin of -404.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides